576 related articles for article (PubMed ID: 31820537)
1. Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.
Senni M; Wachter R; Witte KK; Straburzynska-Migaj E; Belohlavek J; Fonseca C; Mueller C; Lonn E; Chakrabarti A; Bao W; Noe A; Schwende H; Butylin D; Pascual-Figal D;
Eur J Heart Fail; 2020 Feb; 22(2):303-312. PubMed ID: 31820537
[TBL] [Abstract][Full Text] [Related]
2. Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.
Witte KK; Wachter R; Senni M; Belohlavek J; Straburzynska-Migaj E; Fonseca C; Lonn E; Noè A; Schwende H; Butylin D; Chiang Y; Pascual-Figal D;
ESC Heart Fail; 2023 Feb; 10(1):80-89. PubMed ID: 36125177
[TBL] [Abstract][Full Text] [Related]
3. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.
Pascual-Figal D; Wachter R; Senni M; Belohlavek J; Noè A; Carr D; Butylin D
ESC Heart Fail; 2018 Apr; 5(2):327-336. PubMed ID: 29239515
[TBL] [Abstract][Full Text] [Related]
5. Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study.
Straburzynska-Migaj E; Senni M; Wachter R; Fonseca C; Witte KK; Mueller C; Lonn E; Butylin D; Noe A; Schwende H; Lawrence D; Suryawanshi B; Pascual-Figal D;
J Card Fail; 2024 Mar; 30(3):425-435. PubMed ID: 37678704
[TBL] [Abstract][Full Text] [Related]
6. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
[TBL] [Abstract][Full Text] [Related]
7. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Sacubitril/Valsartan Initiation in Inpatient Versus Outpatient Setting: A Retrospective Real World Study.
Chng BLK; Hon JS; Chan H; Zheng Y; Gao F; Teo LYL; Sim KLD
Heart Lung Circ; 2021 May; 30(5):674-682. PubMed ID: 33032893
[TBL] [Abstract][Full Text] [Related]
9. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
Wachter R; Senni M; Belohlavek J; Straburzynska-Migaj E; Witte KK; Kobalava Z; Fonseca C; Goncalvesova E; Cavusoglu Y; Fernandez A; Chaaban S; Bøhmer E; Pouleur AC; Mueller C; Tribouilloy C; Lonn E; A L Buraiki J; Gniot J; Mozheiko M; Lelonek M; Noè A; Schwende H; Bao W; Butylin D; Pascual-Figal D;
Eur J Heart Fail; 2019 Aug; 21(8):998-1007. PubMed ID: 31134724
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
Berg DD; Braunwald E; DeVore AD; Lala A; Pinney SP; Duffy CI; Gurmu Y; Velazquez EJ; Morrow DA
JACC Heart Fail; 2020 Oct; 8(10):834-843. PubMed ID: 32800511
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
Berg DD; Samsky MD; Velazquez EJ; Duffy CI; Gurmu Y; Braunwald E; Morrow DA; DeVore AD
Circ Heart Fail; 2021 Feb; 14(2):e007034. PubMed ID: 33530704
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
Berardi C; Braunwald E; Morrow DA; Mulder HS; Duffy CI; O'Brien TX; Ambrosy AP; Chakraborty H; Velazquez EJ; DeVore AD;
JACC Heart Fail; 2020 Oct; 8(10):859-866. PubMed ID: 32919915
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure.
Skersick PT; Proco D; Sharma-Huynh P; Montepara CA; Rodgers JE
Pharmacotherapy; 2022 Nov; 42(11):837-848. PubMed ID: 36151917
[TBL] [Abstract][Full Text] [Related]
14. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
16. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Seferovic JP; Claggett B; Seidelmann SB; Seely EW; Packer M; Zile MR; Rouleau JL; Swedberg K; Lefkowitz M; Shi VC; Desai AS; McMurray JJV; Solomon SD
Lancet Diabetes Endocrinol; 2017 May; 5(5):333-340. PubMed ID: 28330649
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
[TBL] [Abstract][Full Text] [Related]
18. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL
J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
Velazquez EJ; Morrow DA; DeVore AD; Ambrosy AP; Duffy CI; McCague K; Hernandez AF; Rocha RA; Braunwald E
Am Heart J; 2018 Apr; 198():145-151. PubMed ID: 29653636
[TBL] [Abstract][Full Text] [Related]
20. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
